Engineered extracellular vesicles antagonize SARS-CoV-2 infection by inhibiting mTOR signaling.
Ontology highlight
ABSTRACT: Effective treatment approaches for patients with COVID-19 remain limited and are neither curative nor widely applicable. Activated specialized tissue effector extracellular vesicles (ASTEX) derived from genetically-enhanced skin fibroblasts, exert disease-modifying bioactivity in vivo in models of heart and lung injury. Here we report that ASTEX antagonizes SARS-CoV-2 infection and its pathogenic sequelae. In human lung epithelial cells exposed to SARS-CoV-2, ASTEX is cytoprotective and antiviral. Transcriptomic analysis implicated the mammalian target of rapamycin (mTOR) pathway, as infected cells upregulated mTOR signaling and pre-exposure to ASTEX attenuated it. The implication of mTOR signaling was further confirmed using mTOR inhibition and activation, which increased and decre
SUBMITTER: Ibrahim AG
PROVIDER: S-EPMC8841010 | biostudies-literature | 2022 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA